Article
Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations.
Clinical lung cancer - 1 May 2006
Sakurada Akira, Shepherd Frances A, Tsao Ming-Sound
Abstract excerpt
The discovery of mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) and the positive results of the National Cancer Institute of Canada Clinical Trials Group BR.21 phase III, randomized, placebo-controlled trial of erlotinib in patients with advanced-stage non-small-cell lung cancer that had failed to respond to first- or second-line chemotherapy provides new treatment...
Topics
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Clinical Trials as Topic
- Drug Resistance
- ErbB Receptors
- Genotype
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors
- Survival Rate